Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0ER2C
|
||||
Former ID |
DIB010821
|
||||
Drug Name |
Triptoreline
|
||||
Synonyms |
Triptoreline (microsphere depot formulation, prostate cancer); Triptoreline (microsphere depot formulation, prostate cancer), GP Pharm; Triptoreline (one-month sustained release formulation, prostate cancer), GP Pharm; Triptoreline (three-month sustained release formulation, prostate cancer), GP Pharm
|
||||
Indication | Prostate cancer [ICD9: 185; ICD10:C61] | Phase 4 | [522253] | ||
Company |
GP Pharm SA
|
||||
Structure |
Download2D MOL |
||||
Formula |
C64H82N18O13
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Gonadotropin-releasing hormone receptor | Target Info | Modulator | [528589] | |
NetPath Pathway | IL1 Signaling Pathway | ||||
IL2 Signaling Pathway | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.